Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 622–623 | Cite as

ASO Author Reflections: Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients

  • Rita A. Mukhtar
ASO Author Reflections



The author has no conflicts of interest to disclose.


  1. 1.
    Allison KH, Sledge GW. Heterogeneity and cancer. Oncology (Williston Park). 2014;28:772–8.Google Scholar
  2. 2.
    Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.CrossRefGoogle Scholar
  3. 3.
    Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–205.CrossRefGoogle Scholar
  4. 4.
    Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–29.CrossRefGoogle Scholar
  5. 5.
    Mukhtar RA, Wong J, Piper M, et al. Breast conservation and negative margins in invasive lobular carcinoma: the impact of oncoplastic surgery and shave margins in 358 patients. Ann Surg Oncol. 2018. Scholar
  6. 6.
    Mukhtar RA, Yau C, Rosen M, et al. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013;20:3823–30.CrossRefGoogle Scholar
  7. 7.
    Kuerer HM, van la Parra RF. Breast cancer clinical trials: past half century moving forward advancing patient outcomes. Ann Surg Oncol. 2016;23:3145–52.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Division of General Surgery, Department of SurgeryUniversity of California, San FranciscoSan FranciscoUSA

Personalised recommendations